Invalidity dossier
US 8911751
Compositions for nasal delivery
Current assignee: Yissum Research Development Co of Hebrew University of Jerusalem
Added 9/23/2026, 8:02:11 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US8911751B2 — "Compositions for Nasal Delivery"
Title and identifier: US8911751B2, titled "Compositions for Nasal Delivery" (source: https://patents.google.com/patent/[US8911751](/patent/US8911751)/en).
Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem (original and current assignee listed). Inventors: Elka Touitou, Biana Godin, and Shaher Duchi.
Key dates (as listed; the source states these are assumptions, not legal conclusions):
- Priority date: 2005-10-11; priority claimed from PCT/IL2006/001187 (WO2007043057A2)
- Application US12/078,317 filed: 2008-03-28
- Pre-grant publication US20090047234A1: 2009-02-19
- Grant/publication: 2014-12-16
- Status: Expired – Fee Related; adjusted expiration 2028-11-30
Purpose and plain-language scope: The patent concerns compositions formulated for administration via the nose. Its classifications point to nasal galenical forms (A61K9/0043) and to a broad range of active agents — organic compounds such as alcohols/phenols, carboxylic acids including amino-group-bearing acids (e.g., diclofenac, mefenamic acid, chlorambucil), seven-membered nitrogen heterocycles including 1,4-benzodiazepines, o-phenolic cannabinoids, and peptides — combined with non-active ingredients such as alcohols, glycols/PEG, poloxamers, and other macromolecular carriers. The prior-art keywords listed are "agent," "composition," "mammal," "treatment," and "need," which is consistent with claims directed to treating a mammal in need using such a nasal composition.
What the supplied excerpt does not establish: The excerpt does not include the actual claim text, the written description, examples, or figures, so the precise claimed scope, dosages, specific active agents, or mechanisms cannot be confirmed from it. It also does not establish prosecution history, the full list of cited prior art, or any legal conclusion about validity, infringement, or enforceability. The legal status and expiration shown are expressly stated in the source to be assumptions, not legal conclusions. Per the stated scope of this task, litigation, ownership transfers, validity, and prior art were not researched.
Generated 10/1/2026, 9:41:39 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 8911751. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.